181 related articles for article (PubMed ID: 25231559)
1. Lurasidone suppresses rapid eye movement sleep and improves sleep quality in rats.
Murai T; Nakamichi K; Shimizu I; Ikeda K
J Pharmacol Sci; 2014; 126(2):164-7. PubMed ID: 25231559
[TBL] [Abstract][Full Text] [Related]
2. Lurasidone (latuda®): an atypical antipsychotic.
Nolan SF; Roman MW
Issues Ment Health Nurs; 2012 May; 33(5):342-3. PubMed ID: 22545643
[TBL] [Abstract][Full Text] [Related]
3. Lurasidone for schizophrenia: what's different?
Kantrowitz JT; Citrome L
Expert Rev Neurother; 2012 Mar; 12(3):265-73. PubMed ID: 22364325
[TBL] [Abstract][Full Text] [Related]
4. New drugs. Azilsartan medoxomil, belimumab, and lurasidone hydrochloride.
Hussar DA; Shah A
J Am Pharm Assoc (2003); 2011; 51(3):444-7. PubMed ID: 21555300
[No Abstract] [Full Text] [Related]
5. Effects of some antipsychotics and a benzodiazepine hypnotic on the sleep-wake pattern in an animal model of schizophrenia.
Ishida T; Obara Y; Kamei C
J Pharmacol Sci; 2009 Sep; 111(1):44-52. PubMed ID: 19721330
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
[TBL] [Abstract][Full Text] [Related]
7. Lurasidone: a new treatment option for schizophrenia.
Owen RT
Drugs Today (Barc); 2011 Nov; 47(11):807-16. PubMed ID: 22146224
[TBL] [Abstract][Full Text] [Related]
8. Lurasidone: an atypical antipsychotic for schizophrenia.
Risbood V; Lee JR; Roche-Desilets J; Fuller MA
Ann Pharmacother; 2012; 46(7-8):1033-46. PubMed ID: 22828971
[TBL] [Abstract][Full Text] [Related]
9. Update on the development of lurasidone as a treatment for patients with acute schizophrenia.
Yasui-Furukori N
Drug Des Devel Ther; 2012; 6():107-15. PubMed ID: 22675261
[TBL] [Abstract][Full Text] [Related]
10. The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia.
Monti JM; Torterolo P; Pandi Perumal SR
Sleep Med Rev; 2017 Jun; 33():51-57. PubMed ID: 27321864
[TBL] [Abstract][Full Text] [Related]
11. Ischemic stroke selectively inhibits REM sleep of rats.
Ahmed S; Meng H; Liu T; Sutton BC; Opp MR; Borjigin J; Wang MM
Exp Neurol; 2011 Dec; 232(2):168-75. PubMed ID: 21906592
[TBL] [Abstract][Full Text] [Related]
12. Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid.
Calabrese F; Luoni A; Guidotti G; Racagni G; Fumagalli F; Riva MA
Psychopharmacology (Berl); 2013 Mar; 226(1):101-12. PubMed ID: 23093383
[TBL] [Abstract][Full Text] [Related]
13. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.
Yuen EY; Li X; Wei J; Horiguchi M; Meltzer HY; Yan Z
Mol Pharmacol; 2012 Feb; 81(2):113-9. PubMed ID: 22072817
[TBL] [Abstract][Full Text] [Related]
14. Potential use of lurasidone for the treatment of bipolar psychosis.
Carta MG; Moro MF; Nardi AE; Calabrese JR
Expert Opin Investig Drugs; 2015 Apr; 24(4):575-84. PubMed ID: 25633339
[TBL] [Abstract][Full Text] [Related]
15. [Towards better non-selectivity: the role of 5-HT7 receptors in therapeutic efficacy of a second-generation antipsychotic - lurasidone].
Bieńkowski P; Dudek D; Samochowiec J
Psychiatr Pol; 2015; 49(2):243-53. PubMed ID: 26093589
[TBL] [Abstract][Full Text] [Related]
16. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.
Tarazi FI; Riva MA
Expert Opin Drug Discov; 2013 Oct; 8(10):1297-307. PubMed ID: 23837554
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.
Stahl SM; Cucchiaro J; Simonelli D; Hsu J; Pikalov A; Loebel A
J Clin Psychiatry; 2013 May; 74(5):507-15. PubMed ID: 23541189
[TBL] [Abstract][Full Text] [Related]
18. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.
Potkin SG; Keator DB; Kesler-West ML; Nguyen DD; van Erp TG; Mukherjee J; Shah N; Preda A
CNS Spectr; 2014 Apr; 19(2):176-81. PubMed ID: 24073841
[TBL] [Abstract][Full Text] [Related]
19. Effect of ethanol on sleep-awake state in sleep-disturbed rats.
Obara Y; Tsutsui R; Ishida T; Kamei C
Biol Pharm Bull; 2010; 33(5):849-53. PubMed ID: 20460765
[TBL] [Abstract][Full Text] [Related]
20. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
Potkin SG; Ogasa M; Cucchiaro J; Loebel A
Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
